Iovotibeglogene Autotemcel is a gene therapy commercialized by bluebird bio, with a leading Pre-Registration program in Sickle Cell Disease. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Iovotibeglogene Autotemcel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Iovotibeglogene Autotemcel is expected to reach an annual total of $478 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Iovotibeglogene Autotemcel Overview
Lovotibeglogene autotemcel (bb1111) is under development for the treatment of sickle cell disease (SCD). It is administered through intravenous route as suspension. The therapeutic candidate comprises autologous CD34 positive hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene.
bluebird bio Overview
bluebird bio is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$3.6 million for the fiscal year ended December 2022 (FY2022), a decrease of 1.8% over FY2021. The operating loss of the company was US$287.1 million in FY2022, compared to an operating loss of US$590.9 million in FY2021. The net loss of the company was US$266.6 million in FY2022, compared to a net loss of US$819.4 million in FY2021.
For a complete picture of Iovotibeglogene Autotemcel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.